United Therapeutics Corporation
UTHR
Classement en actions
#1030
United Therapeutics Corporation, a biotechnology firm, is dedicated to... United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Prix de l'action
$533.18
Dernière synchronisation: 2026-10-16
Capitalisation boursière
$22.87B
Changement (1 jour)
-1.54%
Changement (1 an)
23.04%
Pays
US
Échange United Therapeutics Corporation (UTHR)
Catégorie
Healthcare
Marge opérationnelle de United Therapeutics Corporation (UTHR)
Marge opérationnelle au October 2026 TTM : 44.49%
Selon les derniers rapports financiers et le cours de l'action de United Therapeutics Corporation, la marge opérationnelle actuelle (TTM) est de 44.49%. À la fin de 2023, elle était de 50.91%.
Historique de la marge opérationnelle pour United Therapeutics Corporation de 2000 à 2026
Marge opérationnelle à la fin de chaque année
| Année | Marge opérationnelle | Changez |
|---|---|---|
| 2026 (TTM) | 44.49% | -7.04% |
| 2024 | 47.86% | -5.99% |
| 2023 | 50.91% | 0.61% |
| 2022 | 50.60% | 53.43% |
| 2021 | 32.98% | -17.59% |
| 2020 | 40.02% | -409.03% |
| 2019 | -12.95% | -126.17% |
| 2018 | 49.48% | 4.76% |
| 2017 | 47.23% | -28.88% |
| 2016 | 66.41% | 39.25% |
| 2015 | 47.69% | 14.04% |
| 2014 | 41.82% | 59.68% |
| 2013 | 26.19% | -43.10% |
| 2012 | 46.03% | 7.65% |
| 2011 | 42.76% | 57.44% |
| 2010 | 27.16% | 286.34% |
| 2009 | 7.03% | -124.12% |
| 2008 | -29.15% | -1,074.92% |
| 2007 | 2.99% | -83.54% |
| 2006 | 18.16% | -50.92% |
| 2005 | 37.00% | 106.13% |
| 2004 | 17.95% | -183.06% |
| 2003 | -21.61% | -63.84% |
| 2002 | -59.77% | -92.70% |
| 2001 | -818.93% | -79.41% |
| 2000 | -3,977.08% | 0.00% |
Marge opérationnelle pour des entreprises similaires ou concurrentes
| Entreprise | Marge opérationnelle | Différence de Marge Opérationnelle | Pays |
|---|---|---|---|
| 38.59% | -99.13% |
US
|
|
| -149.01% | -103.35% |
US
|
|
| 25.57% | -99.43% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.35% |
NL
|
Qu'est-ce que la Marge opérationnelle d'une entreprise ?
La Marge opérationnelle est un indicateur clé pour évaluer la rentabilité d'une entreprise. Une marge d'exploitation plus élevée est généralement préférable car elle montre qu'une entreprise peut vendre ses produits ou services bien au-dessus de leurs coûts de production. Elle se calcule en divisant les bénéfices par le chiffre d'affaires.